Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Other Operating Expenses (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Other Operating Expenses for 4 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses fell 29.82% to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.8 million, a 13.51% decrease, with the full-year FY2024 number at $6.7 million, up 235.06% from a year prior.
  • Other Operating Expenses was $1.2 million for Q3 2025 at bioAffinity Technologies, down from $1.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $1.8 million in Q4 2024 to a low of $11659.0 in Q4 2022.
  • A 4-year average of $860297.3 and a median of $1.2 million in 2025 define the central range for Other Operating Expenses.
  • Biggest YoY gain for Other Operating Expenses was 14847.35% in 2023; the steepest drop was 62.45% in 2023.
  • bioAffinity Technologies' Other Operating Expenses stood at $11659.0 in 2022, then surged by 14847.35% to $1.7 million in 2023, then rose by 3.32% to $1.8 million in 2024, then crashed by 35.89% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Other Operating Expenses are $1.2 million (Q3 2025), $1.2 million (Q2 2025), and $1.6 million (Q1 2025).